XW043J7 Introduction of Tisagenlecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

Coding Notes

Active
Billable, valid for HIPAA-covered transactions

PCS Table

Section
X New Technology
Body System
W Anatomical Regions
Operation
0 Introduction
Body Part Approach Device / Substance / Technology Qualifier
0 Skin
X External
2 Bromelain-enriched Proteolytic Enzyme
7 New Technology Group 7
1 Subcutaneous Tissue
3 Percutaneous
9 Satralizumab-mwge
7 New Technology Group 7
1 Subcutaneous Tissue
3 Percutaneous
F Other New Technology Therapeutic Substance
5 New Technology Group 5
1 Subcutaneous Tissue
3 Percutaneous
H Other New Technology Monoclonal Antibody
K Leronlimab Monoclonal Antibody
S COVID-19 Vaccine Dose 1
T COVID-19 Vaccine Dose 2
U COVID-19 Vaccine
6 New Technology Group 6
1 Subcutaneous Tissue
3 Percutaneous
W Caplacizumab
5 New Technology Group 5
1 Subcutaneous Tissue
X External
2 Bromelain-enriched Proteolytic Enzyme
7 New Technology Group 7
2 Muscle
3 Percutaneous
S COVID-19 Vaccine Dose 1
T COVID-19 Vaccine Dose 2
U COVID-19 Vaccine
6 New Technology Group 6
3 Peripheral Vein
3 Percutaneous
0 Brexanolone
2 Nerinitide
3 Durvalumab Antineoplastic
6 New Technology Group 6
3 Peripheral Vein
3 Percutaneous
5 Narsoplimab Monoclonal Antibody
7 New Technology Group 7
3 Peripheral Vein
3 Percutaneous
6 Lefamulin Anti-infective
6 New Technology Group 6
3 Peripheral Vein
3 Percutaneous
6 Terlipressin
7 New Technology Group 7
3 Peripheral Vein
3 Percutaneous
7 Coagulation Factor Xa, Inactivated
2 New Technology Group 2
3 Peripheral Vein
3 Percutaneous
7 Trilaciclib
8 Lurbinectedin
7 New Technology Group 7
3 Peripheral Vein
3 Percutaneous
9 Defibrotide Sodium Anticoagulant
2 New Technology Group 2
3 Peripheral Vein
3 Percutaneous
9 Ceftolozane/Tazobactam Anti-infective
6 New Technology Group 6
3 Peripheral Vein
3 Percutaneous
A Bezlotoxumab Monoclonal Antibody
3 New Technology Group 3
3 Peripheral Vein
3 Percutaneous
A Cefiderocol Anti-infective
6 New Technology Group 6
3 Peripheral Vein
3 Percutaneous
A Ciltacabtagene Autoleucel
7 New Technology Group 7
3 Peripheral Vein
3 Percutaneous
B Cytarabine and Daunorubicin Liposome Antineoplastic
3 New Technology Group 3
3 Peripheral Vein
3 Percutaneous
B Omadacycline Anti-infective
6 New Technology Group 6
3 Peripheral Vein
3 Percutaneous
B Amivantamab Monoclonal Antibody
7 New Technology Group 7
3 Peripheral Vein
3 Percutaneous
C Eculizumab
6 New Technology Group 6
3 Peripheral Vein
3 Percutaneous
C Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous
7 New Technology Group 7
3 Peripheral Vein
3 Percutaneous
D Atezolizumab Antineoplastic
6 New Technology Group 6
3 Peripheral Vein
3 Percutaneous
E Remdesivir Anti-infective
5 New Technology Group 5
3 Peripheral Vein
3 Percutaneous
E Etesevimab Monoclonal Antibody
6 New Technology Group 6
3 Peripheral Vein
3 Percutaneous
F Other New Technology Therapeutic Substance
3 New Technology Group 3
3 Peripheral Vein
3 Percutaneous
F Other New Technology Therapeutic Substance
5 New Technology Group 5
3 Peripheral Vein
3 Percutaneous
F Bamlanivimab Monoclonal Antibody
6 New Technology Group 6
3 Peripheral Vein
3 Percutaneous
G Plazomicin Anti-infective
4 New Technology Group 4
3 Peripheral Vein
3 Percutaneous
G Sarilumab
5 New Technology Group 5
3 Peripheral Vein
3 Percutaneous
G REGN-COV2 Monoclonal Antibody
6 New Technology Group 6
3 Peripheral Vein
3 Percutaneous
G Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic
7 New Technology Group 7
3 Peripheral Vein
3 Percutaneous
H Synthetic Human Angiotensin II
4 New Technology Group 4
3 Peripheral Vein
3 Percutaneous
H Tocilizumab
5 New Technology Group 5
3 Peripheral Vein
3 Percutaneous
H Other New Technology Monoclonal Antibody
6 New Technology Group 6
3 Peripheral Vein
3 Percutaneous
H Axicabtagene Ciloleucel Immunotherapy
J Tisagenlecleucel Immunotherapy
7 New Technology Group 7
3 Peripheral Vein
3 Percutaneous
K Fosfomycin Anti-infective
5 New Technology Group 5
3 Peripheral Vein
3 Percutaneous
K Idecabtagene Vicleucel Immunotherapy
7 New Technology Group 7
3 Peripheral Vein
3 Percutaneous
L CD24Fc Immunomodulator
6 New Technology Group 6
3 Peripheral Vein
3 Percutaneous
L Lifileucel Immunotherapy
M Brexucabtagene Autoleucel Immunotherapy
7 New Technology Group 7
3 Peripheral Vein
3 Percutaneous
N Meropenem-vaborbactam Anti-infective
5 New Technology Group 5
3 Peripheral Vein
3 Percutaneous
N Lisocabtagene Maraleucel Immunotherapy
7 New Technology Group 7
3 Peripheral Vein
3 Percutaneous
Q Tagraxofusp-erzs Antineoplastic
S Iobenguane I-131 Antineoplastic
U Imipenem-cilastatin-relebactam Anti-infective
W Caplacizumab
5 New Technology Group 5
4 Central Vein
3 Percutaneous
0 Brexanolone
2 Nerinitide
3 Durvalumab Antineoplastic
6 New Technology Group 6
4 Central Vein
3 Percutaneous
5 Narsoplimab Monoclonal Antibody
7 New Technology Group 7
4 Central Vein
3 Percutaneous
6 Lefamulin Anti-infective
6 New Technology Group 6
4 Central Vein
3 Percutaneous
6 Terlipressin
7 New Technology Group 7
4 Central Vein
3 Percutaneous
7 Coagulation Factor Xa, Inactivated
2 New Technology Group 2
4 Central Vein
3 Percutaneous
7 Trilaciclib
8 Lurbinectedin
7 New Technology Group 7
4 Central Vein
3 Percutaneous
9 Defibrotide Sodium Anticoagulant
2 New Technology Group 2
4 Central Vein
3 Percutaneous
9 Ceftolozane/Tazobactam Anti-infective
6 New Technology Group 6
4 Central Vein
3 Percutaneous
A Bezlotoxumab Monoclonal Antibody
3 New Technology Group 3
4 Central Vein
3 Percutaneous
A Cefiderocol Anti-infective
6 New Technology Group 6
4 Central Vein
3 Percutaneous
A Ciltacabtagene Autoleucel
7 New Technology Group 7
4 Central Vein
3 Percutaneous
B Cytarabine and Daunorubicin Liposome Antineoplastic
3 New Technology Group 3
4 Central Vein
3 Percutaneous
B Omadacycline Anti-infective
6 New Technology Group 6
4 Central Vein
3 Percutaneous
B Amivantamab Monoclonal Antibody
7 New Technology Group 7
4 Central Vein
3 Percutaneous
C Eculizumab
6 New Technology Group 6
4 Central Vein
3 Percutaneous
C Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous
7 New Technology Group 7
4 Central Vein
3 Percutaneous
D Atezolizumab Antineoplastic
6 New Technology Group 6
4 Central Vein
3 Percutaneous
E Remdesivir Anti-infective
5 New Technology Group 5
4 Central Vein
3 Percutaneous
E Etesevimab Monoclonal Antibody
6 New Technology Group 6
4 Central Vein
3 Percutaneous
F Other New Technology Therapeutic Substance
3 New Technology Group 3
4 Central Vein
3 Percutaneous
F Other New Technology Therapeutic Substance
5 New Technology Group 5
4 Central Vein
3 Percutaneous
F Bamlanivimab Monoclonal Antibody
6 New Technology Group 6
4 Central Vein
3 Percutaneous
G Plazomicin Anti-infective
4 New Technology Group 4
4 Central Vein
3 Percutaneous
G Sarilumab
5 New Technology Group 5
4 Central Vein
3 Percutaneous
G REGN-COV2 Monoclonal Antibody
6 New Technology Group 6
4 Central Vein
3 Percutaneous
G Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic
7 New Technology Group 7
4 Central Vein
3 Percutaneous
H Synthetic Human Angiotensin II
4 New Technology Group 4
4 Central Vein
3 Percutaneous
H Tocilizumab
5 New Technology Group 5
4 Central Vein
3 Percutaneous
H Other New Technology Monoclonal Antibody
6 New Technology Group 6
4 Central Vein
3 Percutaneous
H Axicabtagene Ciloleucel Immunotherapy
J Tisagenlecleucel Immunotherapy
7 New Technology Group 7
4 Central Vein
3 Percutaneous
K Fosfomycin Anti-infective
5 New Technology Group 5
4 Central Vein
3 Percutaneous
K Idecabtagene Vicleucel Immunotherapy
7 New Technology Group 7
4 Central Vein
3 Percutaneous
L CD24Fc Immunomodulator
6 New Technology Group 6
4 Central Vein
3 Percutaneous
L Lifileucel Immunotherapy
M Brexucabtagene Autoleucel Immunotherapy
7 New Technology Group 7
4 Central Vein
3 Percutaneous
N Meropenem-vaborbactam Anti-infective
5 New Technology Group 5
4 Central Vein
3 Percutaneous
N Lisocabtagene Maraleucel Immunotherapy
7 New Technology Group 7
4 Central Vein
3 Percutaneous
Q Tagraxofusp-erzs Antineoplastic
S Iobenguane I-131 Antineoplastic
U Imipenem-cilastatin-relebactam Anti-infective
W Caplacizumab
5 New Technology Group 5
9 Nose
7 Via Natural or Artificial Opening
M Esketamine Hydrochloride
5 New Technology Group 5
D Mouth and Pharynx
X External
6 Lefamulin Anti-infective
6 New Technology Group 6
D Mouth and Pharynx
X External
8 Uridine Triacetate
2 New Technology Group 2
D Mouth and Pharynx
X External
F Other New Technology Therapeutic Substance
J Apalutamide Antineoplastic
L Erdafitinib Antineoplastic
5 New Technology Group 5
D Mouth and Pharynx
X External
M Baricitinib
6 New Technology Group 6
D Mouth and Pharynx
X External
R Venetoclax Antineoplastic
T Ruxolitinib
V Gilteritinib Antineoplastic
5 New Technology Group 5
G Upper GI
H Lower GI
7 Via Natural or Artificial Opening
M Baricitinib
6 New Technology Group 6
G Upper GI
H Lower GI
8 Via Natural or Artificial Opening Endoscopic
8 Mineral-based Topical Hemostatic Agent
6 New Technology Group 6
Q Cranial Cavity and Brain
3 Percutaneous
1 Eladocagene exuparvovec
6 New Technology Group 6
V Bones
0 Open
P Antibiotic-eluting Bone Void Filler
7 New Technology Group 7